Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders in Western countries. Recent studies show that almost every multiple myeloma (MM) case is preceded by an MGUS stage. Interestingly, prevalence and incidence patterns for MGUS and MM show striking disparity patterns across ethnic/racial groups, most notably the two-to threefold increase in both these disorders in African Americans compared with Caucasians. In contrast, studies on Asian patients show lower prevalence/ incidence for MGUS/MM compared with Caucasians. Familial aggregation for both MGUS and MM has been observed; the risk for MGUS or MM in family members with these disorders is increased about two-to three fold compared with the general population. Although underlying mechanisms remain unclear, there is evidence of heterogeneity among MGUS patients from different ethnic/racial groups. For example, compared with Caucasians, African-American and African MGUS patients have reportedly lower rates of immunoglobulin M (IgM) MGUS (versus IgG/IgA MGUS) and higher rates of unquantifiable immunoglobulins (Igs). This review focuses on racial disparity and familial aggregation patterns for MGUS and MM and discusses how these observations provide novel clues with regard to pathogenesis.
Introduction
Multiple myeloma (MM) is a clonal plasma cell proliferative disorder with a median survival of B4 years. 1 Approximately 19 900 new MM cases and 10 700 MM deaths occur in the United States annually. 2 Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders in Western countries with a prevalence of 3.2% in the Caucasian population 50 years of age or older. 3 It is characterized by the presence of a monoclonal immunoglobulin (Ig) (M-protein) without evidence of MM or other lymphoproliferative malignancies. 4, 5 Based on data from the Mayo Clinic, long-term follow-up of MGUS patients reveals an average 1% annual risk of developing a lymphoproliferative malignancy. 6, 7 There are also data to suggest that MGUS cases with an abnormal serum-free light chain ratio, non-IgG MGUS and a high-serum M-protein level (X15 g/l) have a 58% absolute risk of developing MM after 20 years of follow-up; in contrast, MGUS cases with none of these risk factors have only a 5% absolute risk of progressing to MM. 4 These observations show a wide variation in the risk of progression to MM among MGUS patients and, importantly, the vast majority of MGUS cases will never develop a lymphoproliferative malignancy. 4 A recent study based on 77 469 healthy adults enrolled in a US nationwide population-based prospective cancer screening trial identified 71 individuals who developed MM during the course of the study. Using serially collected pre-diagnostic serum samples obtained up to almost 10 years before MM diagnosis, all MM cases were found to be preceded by MGUS. 5 In accordance with recent observations, 6 when M-protein and involved-Free light chains (FLC) ratios were evaluated over time in individual patients, about half the study population showed a year-by-year increase before MM diagnosis, whereas the other half maintained largely stable abnormal serum protein level up to the diagnosis of MM. Although it remains to be confirmed, it has been speculated that 'evolving MGUS' potentially could be a marker for an early myeloma with a slow rate of progression. 6 Furthermore, another recent study evaluated 30 MM cases with available pre-diagnostic serum stored in the US Department of Defense Serum Repository. 7 In that study, 27 of the 30 MM cases were found to have a preceding MGUS diagnosis. With regard to the three MM patients, without evidence of an earlier MGUS diagnosis, two had IgD MM and one patient had only one serum sample available X5 years before MM diagnosis (that is, the subject could not be tested for MGUS between 2 and 4 years before MM). This novel observation from two independent studies establishes an essential role for MGUS in the pathway to MM.
Interestingly, there are striking racial disparity patterns in the epidemiology of both MGUS and MM between Caucasians, African Americans and Asians (Table 1 and Figure 1) . 8 Both the disorders are two-to threefold more common in African Americans compared with Caucasians. 9 In fact, MM is the most common hematological malignancy in African Americans. In contrast, among Asians, the prevalence of these disorders is substantially lower. This review will focus on the role of ethnic and genetic factors in the development of monoclonal gammopathies and MM.
MGUS in Caucasians
The concept of monoclonal compared with polyclonal gammopathies was initially raised by Jan Waldenströ m in 1960. 10 He described patients with a narrow band of hypergammaglobulinemia on electrophoresis as having a monoclonal protein. Many of these patients had MM or macroglobulinemia,
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but others had no evidence of malignancy and he considered them to have 'essential hypergammaglobulinemia' or a 'benign monoclonal protein.' Based on the observation that MM, macroglobulinemia, light-chain (AL) amyloidosis, or a related disorder may subsequently develop, Kyle 11 coined the term MGUS in 1978. The largest, population-based study on the epidemiology of MGUS has been performed on the population of Olmsted County, MN, USA whose residents are overwhelmingly Caucasian. 3 In this study, Kyle et al. identified all living residents of Olmsted County as of 1 January 1995. Serum samples were obtained from 21 463 of the 28 038 enumerated residents who were 50 years of age or older (76.6%). In their study, the prevalence of MGUS in patients over the age of 50 was found to be 4.0% in men and 2.7% in women. 3 The prevalence of MGUS rises with the advancing age in this group, with the peak prevalence in those older than 80 years, 8.3% in men and 6.0% in women (Figure 2 ). The Ig isotype was IgG in 68.9%, IgA in 10.8%, IgM in 17.2% and biclonal in 3.0%. Clonal-kappa (k) was present in 62% and lambda (l) in 37% (k:l ratio of 1.67). The median monoclonal protein level was 0.5 mg per 100 ml and 12% of patient had an unquantifiable monoclonal protein.
MGUS in African Americans and Africans
There have been two small studies that have examined the prevalence of MGUS in African Americans. Cohen et al. 12 studied 1732 subjects older than age 70 years residing in a five county area of North Carolina. They performed serum protein electrophoresis (SPEP) with a confirmatory immunofixation electrophoresis (IFE). In this study, they found a twofold difference in the prevalence of MGUS between African Americans (8.4%) and Caucasians (3.8%). The Ig isotype distribution was as follows: 65% IgG, 5% IgA, 10% IgM and 17% biclonal. The k:l ratio was 1.2. The median concentration of the monoclonal protein was not reported, although 40% of African Americans had a concentration o0.5 gm per 100 ml. In another study, Singh et al. 13 evaluated the prevalence of MGUS in a cohort of 397 men and one woman (270 Whites and 128 Blacks) in a hospital setting at the Houston Veterans Affairs Figure 1 The incidence of multiple myeloma around the world (age-adjusted rates per 100 000 person years). 
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Medical Center; study subjects were 20 years or older. In their study, SPEP and IFE were performed for diagnostic purposes in a cohort of patients suspected of a plasma cell or lymphoproliferative disorder. The overall prevalence of MGUS in African Americans was 14.8% compared with 7.8% in Caucasians. The prevalence rate in this study is markedly higher in both races, as this was not a screening population, but rather a diagnostic population, in which SPEP and IFE were ordered for clinical reasons. Furthermore, the IFE was performed on all patients, which also likely accounted for a higher prevalence rate because of the greater sensitivity of IFE for monoclonal proteins. The largest study, to date, to address the prevalence of MGUS in African Americans was performed among 4 million veterans admitted to a Veterans Affairs Hospital over a 16-year period with a hospital discharge diagnosis of MGUS. 9 In this study, the age-adjusted prevalence rate of MGUS was threefold higher in African Americans compared with Caucasians. An important observation in this study was the fact that among 2046 MGUS cases, the estimated cumulative risk of MM during the first 10 years of follow-up was similar (P ¼ 0.37) for African Americans (17%) and Caucasians (15%) (Figure 3 ). Taken together, this study suggests that the excess risk of MM in African-Americans results from an increase in risk of MGUS rather than an increased risk of progression from MGUS to MM.
The first large population-based MGUS screening study from Africa was published in 2007.
14 A total of 917 men, 50 years of age or older from Accra, Ghana were included in this study conducted in collaboration among the University of Ghana, National Cancer Institute and the Mayo Clinic. In this study, Ghanaian males 50 years or older were found to have an ageadjusted MGUS prevalence rate of 5.84%. Compared with males from Olmsted County, MN, USA (age-adjusted MGUS prevalence rate of 2.97%) this translated into a twofold excess among Ghanaian males.
14 As pointed out in the Ghana study, on the basis of self-reported questionnaire data, there was no statistically significant association between MGUS and a history of selected infectious diseases.
14 Neither did the prevalence of MGUS vary by demographic features, ethnicity or education status. Studies based on larger numbers are needed to better assess the association between immune-mediated and inflammatory conditions in relation to MGUS risk. In the MGUS screening study from Ghana, the Ig isotype distribution was as follows: 74% IgG, 19% IgA, 6% IgM and 2% biclonal. Clonal-k was present in 48% and clonal-l was present in 50% (k:l ratio of 0.96). A total of 76% of the MGUS patients had unquantifiable monoclonal protein concentrations. For the remaining MGUS patients, the mean monoclonal protein concentration was 0.97 g per 100 ml. In contrast to Caucasians, a rising prevalence of MGUS with increasing age was not found in the Ghanaian male population ( Figure 2) .
As shown in Figure 1 , the highest reported MM incidence worldwide is found among African Americans. The second highest MM incidence is found on the French island Martinique, which is located between the Caribbean Sea and the North Atlantic Ocean, north of Trinidad and Tobago (Figure 1) . Most of Martinique's population is descended from Africans brought to work on sugar plantations during the colonial era, generally mixed with some French, Amerindian (Caribbean people), Indian (Tamil), Lebanese or Chinese population. 15 Indeed, African and African-White-Indian mixture add up to a total of 90%; 5% are White; and o5% are East Indian and Chinese. Our finding of an increased incidence of MM in Martinique is in accordance with an earlier smaller study based on 208 MM patients seen at the University Hospital in Fort de France, Martinique. 16 Owing to the lack of large central Cancer registries in Africa, at this time, there is virtually no reliable information available on the incidence of MM across different African populations.
MGUS in Asians
The epidemiology of MGUS in Asian populations was first described in a small study by Bowden. 17 The investigators used a convenience sample of well-elderly (X60 years old) patients from a community center in Yokohama, Japan (n ¼ 146) and compared this with a retirement community in the United States. (n ¼ 111). The overall prevalence in the Japanese cohort was 2.7% compared with 10% in the US cohort. Although an age-related increase in the prevalence of MGUS was seen among the US cohort, this was unable to be detected in the Japanese cohort as there were no cases of MGUS in the 80-89-year-old group and no patients older than 90 years. This lower prevalence of MGUS is in keeping with the lower incidence of MM in Japan; however, larger studies are needed to confirm this finding. 18 This lower prevalence has been confirmed in large studies of atomic bomb survivors in Japan. Recently, Iwanaga et al.
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screened 52 802 men and women who had survived the atomic bomb detonation in Nagasaki. A total of 1088 MGUS cases were detected for an overall prevalence of 2.1%, when restricted to those over the age of 50 years the prevalence was 2.4%. The Ig isotype was IgG in 73.6%, IgA in 17.7%, IgM in 7.5% and biclonal in 1.1%. Clonal-k light chains were expressed in 56% and clonal-l light chain in 41% (ratio of 1.4). There was an agerelated increase in the prevalence of MGUS in each decade over the age 50 years: 1.9% (50-59), 2.6% (60-69), 3.0% (70-79) and 4.4% (X80). The significantly lower incidence of MGUS in this Japanese population is even more notably given that they were exposed to radiation. The role of radiation in the development of MGUS and MM is not clear, although there is recent evidence to suggest that it may contribute to the development of these disorders, particularly in those exposed to higher doses at a younger age. 20 Thus, it is possible that the prevalence of MGUS in a non-radiation-exposed Japanese population is even lower. Aside from the lower prevalence of MGUS in the Japanese population other clinical features, that is, isotype and age distribution, appear similar to that seen in the Caucasians.
Familial aggregation of MM
Familial clustering of myeloma was first mentioned in the 1920s and has subsequently been reported in case reports, 
Years
Cumulative risk (%) Figure 3 The cumulative risk of progression to myeloma among African-American and Caucasian MGUS patients.
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Leukemia case-control and cohort studies. [21] [22] [23] [24] [25] [26] [27] [28] [29] Recently, Lynch 30 described a remarkable family of seven siblings in which three had MM and two had MGUS. Serum and urine electrophoresis in 19 other family members of this sibship only revealed two cases of MGUS. In a descriptive study of 39 families with multiple cases of MM or related disorders, several interesting findings were noted. 29 The median age at diagnosis, 62 years, is substantially younger than the general MM population. There was a slight female predominance (52%), which is also contrary to the general myeloma population. In addition, the authors suggested evidence of anticipation with a decreasing age at diagnosis in successive generations (mean age 75 years in the first generation and 61 years in the second generation). In addition, several other cancer types were found in other family members, most commonly leukemia and lymphoma (32 patients), colon cancer (18 patients) and pancreatic cancer (10 patients). The findings from this descriptive study should be taken with caution as these families were derived from collaborating research centers and not part of a systematic prospective study.
The largest familial MM study to date was based on Swedish central databases. A population-based, case-control study including 8406 MM patients diagnosed in Sweden (1958-1998), 16 543 matched population-based controls, and first-degree relatives of MM patients (n ¼ 22 490) and controls (n ¼ 44 436) found a 1.7-fold significantly increased risk for MM in relatives of MM cases compared with relatives of controls ( Table 2) . 31 This risk was higher in female relatives (Relative risk (RR) ¼ 3.74), relatives of probands X65 years old at diagnosis of MM and among relatives of female probands (RR ¼ 3.97). The preponderance of female patients in familial MM is in contrast to the general MM population; the underlying mechanisms for this finding remain unclear. Importantly, in this large population-based study, the age at MM diagnosis was very similar for relatives of cases and controls. This observation suggests that familial myeloma does not present at an earlier age than sporadic MM as has been found in other non-populationbased studies. Likely, the reported younger age of MM onset in successive generations is an artifact driven by database truncation and reporting bias. 32 To our knowledge, there have been only a few reports of familial MM in African Americans. Lynch et al. 33 described an African-American family with five cases of MM, three case of MGUS and five cases of prostate cancer among 11 first-degree relatives. Jain et al. 34 reported on eight African-American families with familial MM and MGUS seen in a 30-year period at a single institution. A total of 21 of 58 first-degree relatives had a plasma cell dyscrasia including 12 MM, eight MGUS and one amyloidosis. Additional malignancies were found 21 other family members, most commonly leukemia, lymphoma and myeloproliferative disorders (n ¼ 5), breast cancer (n ¼ 4), prostate cancer (n ¼ 3) and colon cancer (n ¼ 3). 34 
Familial aggregation of MGUS
A few case reports and smaller studies have found evidence of familial clustering of MGUS. Recently, the first large populationbased familial MGUS study was conducted. Using populationbased data from Sweden, a total of 4458 MGUS patients, 17 505 population-based controls and first-degree relatives of patients (n ¼ 14 621) and controls (n ¼ 58 387) were identified. 35 In this study, compared with relatives of controls, relatives of MGUS patients were found to have a significantly increased risk of MGUS (RR ¼ 2.8), MM (RR ¼ 2.9), lymphoplasmacytic lymphoma/ Waldenströ m's macroglobulinemia (LPL/WM) (RR ¼ 4.0) and chronic lymphocytic leukemia (RR ¼ 2.0) ( Table 2 ). Based on small numbers, relatives of patients with IgG/IgA MGUS had a 4.0-fold, 2.9-fold and 20-fold elevated risk of developing MGUS, MM and LPL/WM, respectively; relatives of IgM MGUS patients had 5.0-fold increased chronic lymphocytic leukemia risk and non-significant excess MM and LPL/WM risks. The results were very similar when risk was assessed by the type of first-degree relative, age at MGUS (above/below 65 years) or sex. The risk of lymphoma was not increased among MGUS relatives.
Similarly, the Mayo Clinic group sought to determine the risk of MGUS in first-degree relatives of patients with both MGUS and MM. 36 They invited 304 MGUS patients and 407 MM patients seen at their institution to participate. Each of these patients was asked to provide informed consent and a family history questionnaire, including names and addresses of firstdegree relatives. For each consenting proband, the first-degree relatives were mailed a consent form and a blood collection kit. SPEP, IFE and serum-free light chain analyses were performed to screen for a monoclonal gammopathy. A total of 911 relatives agreed to participate in the study and provided blood samples, including 247 of 574 (43%) first-degree relatives of MGUS probands and 664 of 1186 (56%) MM probands. The age-and sex-adjusted prevalence of MGUS in MGUS probands was 4.5% and of MM probands was 7.4% on the basis of SPEP with confirmatory IFE. When all three tests were performed (SPEP, IFE and sFLC) to detect a monoclonal gammopathy, the prevalence of MGUS in relatives of MGUS probands was 10.9% and in relatives of MM probands it was 7.0%. Using the Olmsted County population as a reference, the prevalence of MGUS in first-degree relatives of MGUS and MM patients was Btwo-to threefold higher (Table 2 ). This association was present across age, gender and relationship of first-degree relative. Increasing Table 2 Relative risk of developing MGUS or MM among first-degree relatives of MGUS or MM patients (versus first-degree relatives of controls), respectively
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Relative risk of developing MM among first-degree relatives of patients (versus first-degree relatives of controls)
Relative risk of developing MGUS among first-degree relatives of patients (versus first-degree relatives of controls)
Myeloma patients Swedish study 31 1.67 2.96 Mayo Clinic study 36 
ND
2.00
MGUS patients
Swedish study 35 2.90 2.80 Mayo Clinic study 36 
ND
3.30
Abbreviations: MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; ND, not done.
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prevalence of MGUS with increasing age was seen in relatives of both MGUS and MM probands. There was a trend toward a higher risk of MGUS in relatives for probands with a monoclonal protein greater than 1.5 g per 100 ml; however, the discrepancy was not statistically different. There was no difference in risk for MGUS by Ig isotype. Although this study was relatively small and there was a low response rate to the questionnaires, the results of this study are quite similar to the results of the Swedish population-based studies. Inspired by recent familial MM studies suggesting excess of certain solid tumors among blood relatives to MM patients, 33, 37 we recently conducted, to our knowledge, the first populationbased study to evaluate familial aggregation patterns of 27 solid tumors and all myeloid hematological malignancies among firstdegree blood relatives of MGUS patients. 38 Compared with relatives of controls (n ¼ 58 387), first-degree relatives of MGUS patients (n ¼ 14,621) had a 10% (P ¼ 0.004) increased risk of developing solid tumors (including all tumors). When we assessed individual tumor sites, we found evidence of a significantly increased risk for bladder cancer (RR ¼ 1.4; P ¼ 0.035) and, based on small numbers (six cases and eight controls), a 3.0-fold (P ¼ 0.033) increased risk for spinal cord cancer. We also found borderline increased risks for malignant melanoma (RR ¼ 1.3; P ¼ 0.051) and lung cancer (RR ¼ 1.2; P ¼ 0.078). No significantly increased risk was found for any of the other solid tumor sites or for myeloid hematological malignancies. Although the excess risks were found to be quite small, these findings support a role for a shared susceptibility (genetic, environmental, or both) that predisposes to MGUS and certain solid tumors, supporting the application of gene mapping and candidate gene approaches in high-risk families and case-control studies.
Other clinical and biological racial disparity patterns
The features of MGUS in African Americans compared with Caucasians show distinct differences. The two-to three fold increased prevalence of MGUS in Blacks, both residing in the United States and in Africa is highly suggestive of a role for susceptibility genes in the causation of MGUS/MM. There are no studies that have isolated a specific genetic locus. One study evaluated HLA alleles and found that there is an increased frequency of Cw2 in both African Americans and Caucasians that may increase the susceptibility to MM, but could not account for the increased incidence in African Americans. 39 The age distribution of the prevalence of MGUS between the races is also quite striking, with African Americans (compared with Caucasians) having virtually the same elevated prevalence rates between the ages 50 and 79 years, whereas Caucasians have a continuous increase in prevalence with age ( Figure 2 ). This observation supports the idea that MGUS develops earlier in African Americans, which is also consistent with the observed earlier onset of MM among African Americans compared with Caucasians. 40 Indeed, earlier age of onset, is further supportive of genetic factors in the etiology of MGUS/MM. As mentioned above, we found recently elevated risks of MGUS, MM, LPL/ WM and chronic lymphocytic leukemia among first-degree relatives of MGUS patients (compared with relatives of controls), supporting a role for shared germline susceptibility genes, shared environmental influences, or a combination. 35 There is only limited information available on potential racerelated variation with regard to disease-and host-related factors in MGUS and MM. Although the literature is sparse, there seem to be different features of MGUS in African Americans and Africans compared with Caucasians. For example, the prevalence of IgM MGUS is significantly lower among Blacks compared with Caucasians, which is also in keeping with the ethnic distribution in WM. 41, 42 In the three studies of African Americans, there is a discrepancy in the ratio of k:l. In the Ghana and North Carolina studies (discussed under MGUS in African Americans and Africans), the ratio of k:l disorders is nearly equivalent; however, in the study from Texas, the ratio of k:l disorders is 2.5. In the latter study, both SPEP and IFE were performed in a diagnostic population, and not in a screened population, thus it is difficult to compare these studies. The most striking difference between these populations is the large number of patients with unquantifiable monoclonal Igs in the study from Ghana (76%), compared with Olmsted County, MN, USA (12%). In the North Carolina study, the proportion of African Americans with a monoclonal Ig o0.5 g per 100 ml, was 40% compared with 59% in Caucasians. However, the proportion with unquantifiable monoclonal Igs was not reported in this study. One possible explanation for this finding is a difference in the response to immune stimulation between the races as these are putative triggers for the development of MGUS/MM. 8, 43, 44 In addition, the differences between the study of African Americans compared with Ghanaians suggest the possibility of differing environmental exposures, such as infectious agents or toxins, which may result in differing the immune responses. In the Ghana study, the self-reported history of infections did not show any association with the development of MGUS. However, as pointed out in that study, there might be an influence of some immune-related conditions that were not captured in the study questionnaire. In fact, in a large study from the US Veteran's Affairs system, a history of autoimmune, infectious and inflammatory conditions were associated with an increased risk for MGUS and MM; risk seemed to be equal between the races. 44 Although gene-expression profiling and cytogenetic analysis in MM reveal evidence of heterogeneity reflected in markedly different clinical outcomes, [45] [46] [47] to our knowledge, no large studies have specifically addressed the molecular features of MM across ethnic groups. A few studies have compared survival patterns between African-American and Caucasian patients treated with both conventional therapy and autologous stem cell transplantation and have reported similar outcomes. [48] [49] [50] As it cannot be ruled out that there are differences with regard to access to care, referral bias and other types of biases, there is need for larger studies assessing MM outcomes by race. Ideally such studies should include molecular analyses.
Future directions
Future studies, including genetic mapping by admixture linkage disequilibrium applied to African-American populations with MM or MGUS, could provide insights into the etiology and pathogenesis of MGUS and risk factors for MM progression. [51] [52] [53] In addition, the role for immune-related factors in myeloma genesis needs to be better defined. Furthermore, the underlying mechanisms of observed clinical differences among AfricanAmerican, Asian and Caucasian MGUS cases remain to be elucidated; 3, 14, 19 future studies are needed to confirm and expand on these observations. For example, there is a need to evaluate serum-free light chain assays among African Americans, particularly because of the large number of patients in Ghana with unquantifiable monoclonal proteins. In parallel, we need to improve our understanding with regard to mechanisms that mediate monoclonal plasma cell proliferation, survival and
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Genetic factors in MGUS and myeloma O Landgren and BM Weiss migration in the bone marrow microenvironment. Such efforts will ultimately enhance our understanding of MGUS and MM pathophysiology and allow identification of novel molecular targets. 54 
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